Rezpegaldesleukin Demonstrates Broad Phase 2b Efficacy in Atopic Dermatitis and Asthma

Rezpegaldesleukin significantly improved disease severity, itch, and asthma-related symptoms in patients with moderate-to-severe atopic dermatitis, according to “Rezpegaldesleukin, Novel Treg-Inducing Therapy, Demonstrates Efficacy in Atopic Dermatitis and Asthma in a Phase 2b Trial,” a poster by Raj Chovatiya, MD, PhD, et al presented as part of the “Best of the Best at Maui Derm” late breakers session at Maui Derm Hawaii 2026.

At Week 16, rezpegaldesleukin 24 µg/kg administered every two weeks met the primary endpoint, demonstrating a statistically significant mean percent reduction in EASI score versus placebo (p<0.001). Key secondary endpoints—including EASI-75, EASI-90, vIGA-AD 0/1, and itch numeric rating scale improvements—were also met.

Notably, patients with a history of asthma experienced improvements in self-reported asthma control, supporting the drug’s immunomodulatory mechanism. “These findings support further development of rezpegaldesleukin as a novel biologic treatment for atopic dermatitis and asthma,” the authors noted.

Safety findings were consistent with previous studies, with no new safety signals, low discontinuation rates, and predominantly mild injection-site reactions.

“This is a completely novel approach,” said Jason E. Hawkes, MD. “Instead of blocking inflammation downstream, rezpegaldesleukin is designed to promote regulatory T-cell function and help the immune system calm itself down.”

Dr. Hawkes noted that improvement in comorbid asthma was particularly notable.

“Seeing benefit across multiple type 2 inflammatory diseases reinforces that this mechanism could have broad applicability beyond just atopic dermatitis,” he said.